Q-omics provides the consensus-scored PRXL2B profile across patient tissues and cancer cell-line models. PRXL2B expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, PRXL2B is differentially expressed in 15, with the highest sampling consensus in LIHC. Additionally, PRXL2B protein abundance shows 21,948 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight UVM, LIHC, and PDAC as cancer lineages where PRXL2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRXL2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRXL2B survival associations across molecular data types. PRXL2B RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRXL2B RNA expression–survival associations across cancer types. High PRXL2B expression shows unfavorable associations in ACC and LIHC, but favorable associations in UVM, DLBC, KIRC and MESO. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for PRXL2B RNA expression.
This table summarizes PRXL2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in LIHC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for PRXL2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRXL2B shows lower tumor expression in KICH and higher tumor expression in LIHC, STAD, BRCA, BLCA and HNSC. The LIHC box plot shows higher PRXL2B RNA expression in tumor versus normal tissue (log2 FC = +1.790, t-test p < 0.001).
This table shows molecular features associated with PRXL2B in patient tissues and cancer cell lines. In patient samples, PRXL2B shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, PRXL2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BONE and LUNG_SCLC.
